| abstract |
Provided are a biomarker composition for the diagnosis of moyamoya disease, including caveolin-1, a kit for the diagnosis of moyamoya disease, a method of providing information for moyamoya disease diagnosis, and a method of screening a moyamoya disease therapeutic agent. According to the present disclosure, specific treatment for moyamoya disease is possible by distinguishing the disease from atherosclerosis, which is a similar cerebrovascular stenosis disease, and thus unnecessary factors or risk factors that may be accompanied by side effects may be avoided and, therefore, may be applied to effective MMD therapies. |